Kangstem Biotech

What Kangstem Biotech does

Kangstem Biotech is a KOSDAQ-listed South Korean biotechnology company developing cell therapeutics based on allogeneic umbilical cord blood-derived mesenchymal stem cells (MSCs). Founded in 2010 and headquartered in Seoul, the company operates across five business lines: the Furestem stem-cell therapy franchise (Furestem-AD for atopic dermatitis, Furestem-OA for osteoarthritis, Furestem-RA for rheumatoid arthritis), the OSCA combination product pairing Furestem-OA with acellular cartilage matrix for knee osteoarthritis, organoid platforms (skin and islet organoids) for drug screening and regenerative medicine, CDMO services for cell-therapy developers via in-house GMP manufacturing, and the GD-11 cell-bio-derma cosmetic brand built on the proprietary USC1994 culture medium. The underlying technology is anchored in the SELAF™ one-stop platform covering cell separation, expansion, and clinical production.

The company's revenue model is diversified across product sales of stem-cell therapies and cosmetic SKUs, CDMO service contracts (notably with YJ Therapeutics for neural-progenitor cell therapy manufacturing that achieved IND approval), technology licensing and milestone payments from global pharma partnerships, and emerging organoid product sales. GTM is a hybrid of consumer e-commerce for GD-11 in Korea, enterprise field sales for CDMO and licensing deals, and event-driven partnership development at conferences such as BIO USA, where approximately 20 global pharmaceutical companies have been engaged for OSCA and organoid platform discussions.

Strategic positioning targets disease-modifying osteoarthritis drugs (DMOADs), an unmet category where no approved therapy modifies disease progression, with positive Phase 1 readouts (sustained through 24 months) and a 113-patient Phase 2a trial advancing toward topline in July 2026. The business is currently loss-making at scale (FY2025 net loss approximately KRW 96 billion against KRW 36 billion in revenue), consistent with a clinical-stage biotech in heavy R&D investment mode, offset by improving tax-loss carryforward ratios that have reduced KOSDAQ administrative risk from 52% in 2023 to 14% in 2025.

Name

Kangstem Biotech

Legal name

강스템바이오텍 (주)

Website

https://kangstem.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Kangstem Biotech is a KOSDAQ-listed South Korean biotech developing allogeneic umbilical cord blood-derived mesenchymal stem cell therapies (Furestem line), organoid platforms, CDMO services, and a consumer health brand (GD-11), serving pharmaceutical companies and cell therapy developers.

Ownership category

akta.pro rank

Product category

Cell Therapy / Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell Therapy CDMO (HLAGABAD)

Keywords

• Stem cell therapy
• Regenerative medicine
• Organoid technology
• CDMO services
• Biopharmaceuticals

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Stem Cell Therapeutics): Revenue from stem cell therapy products including Furestem-AD for atopic dermatitis and other pipeline products. The company reported approximately 36 billion KRW in sales revenue for 2025.
2. Technology Licensing and Milestone Payments: Technology transfer contracts generating recurring milestone payments. In 2026, technology transfer contracts are expected to generate 2nd milestone payments, contributing additional revenue alongside existing sales.
3. CDMO Services: Contract development and manufacturing services for cell therapy products. Kangstem provides manufacturing process development, GMP clinical trial material production, and regulatory support for clients like YJ Therapeutics.
4. Organoid Product Sales: Sales of organoid products for research and pharmaceutical applications. Expected to generate additional revenue in 2026.
5. Health & Beauty Products (GD-11): Cell bio-derma cosmetic brand based on international patented technology and USC1994 cell culture medium ingredients.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Kangstem Biotech develops and manufactures stem cell therapeutics targeting degenerative and inflammatory diseases such as osteoarthritis, atopic dermatitis, and rheumatoid arthritis, alongside organoid platforms for drug discovery and cosmetic applications. The company operates GMP manufacturing facilities, provides CDMO services for third-party cell therapy developers, and commercializes a dermo-cosmetic line (GD-11) based on its stem cell technology.

Product overview

Kangstem Biotech is a global cell therapy pioneer developing stem cell-based treatments and organoid platforms. The portfolio centers on allogeneic umbilical cord blood-derived mesenchymal stem cell therapies including Furestem-AD (atopic dermatitis), Furestem-OA/OSCA (osteoarthritis), and Furestem-RA (rheumatoid arthritis), alongside an Organoid platform (skin and islet organoids) for drug screening and regenerative medicine. The company operates CDMO services leveraging GMP facilities, offers stem cell culture media products, and commercializes the GD-11 health and beauty cosmetic brand. The SELAF technology platform provides end-to-end stem cell development capabilities from isolation through clinical production.

Differentiator

Problem solved

Functional benefit

Brands

• Furestem: Stem cell therapeutic product line including Furestem-OA Kit Inj. (osteoarthritis), Furestem-AD Inj. (atopic dermatitis), Furestem-RA Inj. (rheumatoid arthritis)
• SELAF
• OSCA
• GD-11
• Organoid

Products and services

• Furestem-OA Stem cell therapy indicated for osteoarthritis, designed to regenerate cartilage and reduce inflammation in joints. Targeted at hospitals and orthopedic clinics treating patients with degenerative joint disease.
• Furestem-AD Stem cell therapy indicated for atopic dermatitis, providing anti-inflammatory and immunomodulatory effects for chronic skin conditions. Targeted at dermatology clinics and hospitals.
• Furestem-RA Stem cell therapy for rheumatoid arthritis, addressing autoimmune inflammation of joints. Targeted at hospitals and rheumatology specialists.
• OSCA Allogeneic stem cell therapy product undergoing clinical trials, leveraging the company's cell therapy capabilities.
• Skin Organoids Three-dimensional skin organoid platform derived from stem cell technology, used for drug discovery, toxicity testing, and cosmetic research applications. Targeted at research institutions and cosmetic companies.
• Islet Organoids Islet organoid platform for diabetes research and drug development, leveraging stem cell-derived organoid technology. Targeted at pharmaceutical companies and research institutions.
• CDMO Services Contract Development and Manufacturing Organization services for cell therapy developers and biopharmaceutical companies, leveraging GMP-certified manufacturing capabilities and the SELAF™ platform. Targeted at biotech and pharma companies requiring cell therapy manufacturing capacity.
• GD-11 Dermo-Cosmetic Line Dermo-cosmetic product line developed from the company's stem cell technology and byproducts, marketed for skincare applications. Targeted at retail consumers seeking biotech-derived skincare.

Quantifiable outcome

• OSCA Phase 1: Significant pain and function improvement over time in medium and high dose groups, with complete recovery in some subjects. MRI analysis showed cartilage structure improvement signals.
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Seoul National University (서울대학교)coreStrategic or Co-development Partner · 30 April 2026Joint research collaboration for skin and hair follicle organoid manufacturing standardization. Seoul National University handles organoid source technology development and technology transfer, while Kangstem leads technology verification, standardization, and commercialization system establishment. This partnership is part of a 3-year government-supported project (2026-2028) focused on establishing manufacturing processes and quality control systems for organoid production.
• YJ Therapeutics (와이제이세라퓨틱스)coreStrategic or Co-development Partner · 13 February 2026CDMO partnership where Kangstem provides cell therapy manufacturing process development, GMP clinical trial material production, and regulatory submission support. YJ Therapeutics is developing cross-differentiated neural progenitor cell therapies for spinal cord injury, Parkinson's disease, and ALS. Kangstem supported their successful IND approval for 1/2a phase clinical trial.
• OSI (Organoid Standards Initiative) - Skin DivisionminorStrategic or Co-development PartnerActive participation in OSI's skin division technical committee to establish skin organoid standardization guidelines. Results published in International Journal of Stem Cells (2024.05) demonstrating international standardization capabilities.
• Primoristem Therapeutics (프리모리스테라퓨틱스)coreStrategic or Co-development PartnerExosome technology development specialist and related entity. Consolidation of this entity contributed to 2025 net loss reduction through equity valuation gains. The partnership brings exosome technology capabilities to Kangstem's platform.
• Multiple Global Pharmaceutical CompaniescoreStrategic or Co-development PartnerApproximately 20 global pharmaceutical companies engaged for OSCA (osteoarthritis treatment) and skin/hair follicle organoid platform partnerships. Discussions cover joint development, technology licensing, and commercialization. One major global pharma company conducted on-site visits to Kangstem's research facilities and production facilities. Partnerships expected to advance through BIO USA 2026 discussions.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medipost: Korean biotech commercializing Cartistem (umbilical cord blood-derived MSC therapy for cartilage regeneration). Closest direct peer to Kangstem in allogeneic MSC cartilage repair and Korean cell therapy commercialization.
• Pharmicell: Korean stem cell therapy company with approved autologous bone marrow MSC product Hearticellgram-AMI. Directly comparable as a Korean-listed stem cell therapeutics company with GMP manufacturing capability.
• Corestem: Korean biotech developing autologous stem cell therapy (Neuromast) for ALS. Comparable as a KOSDAQ-listed clinical-stage cell therapy company targeting rare/neuro indications.
• NatureCell: Korean stem cell company with approved autologous MSC product (Cartistem predecessor) and broader regenerative medicine pipeline. Comparable in cell therapy focus and Korean market context.
• Mesoblast: Global leader in allogeneic MSC-based therapies (e.g., Remestemcel-L). Closest international comparable to Kangstem in allogeneic MSC pipeline scope and disease-modifying regenerative medicine positioning.

Broad incumbents

• Samsung Biologics: Large Korean biopharma CDMO and biologics manufacturer. Comparable as a Korean-headquartered CDMO serving global biopharma, though operating at much larger scale and broader scope than Kangstem's cell therapy CDMO.
• Lonza Group: Global leader in cell and gene therapy CDMO services. Comparable as an established cell therapy CDMO peer that Kangstem's GMP services compete against for clinical-stage cell therapy clients.
• Catalent: Major global CDMO with cell therapy manufacturing capabilities. Comparable as a large, established CDMO serving cell therapy developers that competes for similar clinical-stage CDMO contracts.
• Celltrion: Leading Korean biopharmaceutical company expanding into biosimilars and novel biologics. Comparable as a Korean-listed biopharma with broad therapeutic pipeline and global commercialization ambitions.

Emerging players

• Fate Therapeutics: Clinical-stage US cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies. Comparable as a stem/cell therapy platform peer focused on allogeneic, off-the-shelf modalities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kangstem-biotech-co-ltd-
• Xx.com/kangstem
• Facebookfacebook.com/kangstembiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kangstem Biotech